Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- OMGA
- Price
- 0.04
- Stock movement down
- -0.00 (-4.65%)
- Company name
- Omega Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.27M
- Ent value
- 113.08M
- Price/Sales
- 0.28
- Price/Book
- 0.20
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -98.64%
- 3 year return
- -81.15%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
OMGA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.28 |
| Price to Book | 0.20 |
| EV to Sales | 13.97 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 55.37M |
| EPS (TTM) | -1.33 |
| FCF per share (TTM) | -1.04 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 8.10M |
| Gross profit (TTM) | -4.84M |
| Operating income (TTM) | -74.15M |
| Net income (TTM) | -73.09M |
| EPS (TTM) | -1.33 |
| EPS (1y forward) | -0.93 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -59.81% |
| Operating margin (TTM) | -916.00% |
| Profit margin (TTM) | -902.93% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 30.38M |
| Net receivables | 486.00K |
| Total current assets | 38.95M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 152.73M |
| Accounts payable | 1.43M |
| Short/Current long term debt | 128.13M |
| Total current liabilities | 24.17M |
| Total liabilities | 141.18M |
| Shareholder's equity | 11.54M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -55.58M |
| Capital expenditures (TTM) | 2.06M |
| Free cash flow (TTM) | -57.64M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -633.21% |
| Return on Assets | -47.86% |
| Return on Invested Capital | -266.16% |
| Cash Return on Invested Capital | -209.89% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.06 |
| Daily high | 0.07 |
| Daily low | 0.04 |
| Daily Volume | 85K |
| All-time high | 29.38 |
| 1y analyst estimate | 9.50 |
| Beta | 1.84 |
| EPS (TTM) | -1.33 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 20 Jun 2025 |
Downside potential
Loading...
Downside potential data
| OMGA | S&P500 | |
| Current price drop from All-time high | -99.85% | -14.41% |
| Highest price drop | -99.97% | -56.47% |
| Date of highest drop | 7 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -78.36% | -11.07% |
| Avg time to new high | 78 days | 12 days |
| Max time to new high | 866 days | 1805 days |
COMPANY DETAILS
Marketcap
2.27M
Marketcap category
Small-cap
Description
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Employees
93
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner